PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each...
Transcript of PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each...
![Page 1: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/1.jpg)
PRINCIPLES OF ONCOLOGICALTREATMENT
DANK MAGDOLNASE ÁOK I SZ. BELGYÓGYÁSZATI KLINIKA
![Page 2: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/2.jpg)
The place of decision: the Onkoteam
clinical oncologist
radiotherapist
Surgeon -organ specific training is needed
pathologist
psychologist
Special trainer _ phonyatry, dietetics
The Basic of the decision is the pathological result, informing about malignancy
![Page 3: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/3.jpg)
Mire alapozza döntését az onkoteam?”
Imagines Path result (TNM)
Molecular path findings
Performance status
comorbidities
Patient’s preference
The biological behavior of the tumor
Evidence basedmedicine
Guidelines
Cost-effectivness
Financial questions
![Page 4: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/4.jpg)
Approaches to Drug Treatment
• DARK BLUE LINE: Infrequent scheduling of
treatment courses with low (1 log kill) dosing and a late start prolongs survival but does not cure the patient (i.e., kill rate < growth rate)
• LIGHT BLUE LINE: More intensive and frequent treatment, with adequate (2 log kill) dosing and an earlier start is successful (i.e. kill rate>growth rate)
• GREEN LINE: Early surgical removal of the primary tumour decreases the tumour burden. Chemotherapy will remove persistant secondary tumours, and the total duration of therapy does not have to be as long as when chemotherapy alone is used.
![Page 5: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/5.jpg)
Antibiotics
Antimetabolites
S(2-6h)
G2
(2-32h)
M(0.5-2h)
Alkylating agents
G1
(2-h)
G0
Vinca alkaloids
Mitotic inhibitors
Taxoids
Principles of chemotherapy
Cell cycle level
Action sites of cytotoxic agents
![Page 6: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/6.jpg)
How to use chemotherapy?
Neoadjuvant or induction therapy
Adjuvant therapy
Palliativ therapy 1st L, 2nd L, 3rd L, salvage
Intrathecal, intraperitoneal,TACE, TAE
![Page 7: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/7.jpg)
What is metronomic chemotherapy?
• low doses of chemotherapy administered more frequently and regularly, such as weekly or daily
• In contrast, conventional chemotherapy is given at maximum tolerated dose (MTD) every 3weeks at doses just below what would cause over 50% of patients to experience severe or dose-limiting toxicity
![Page 8: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/8.jpg)
Anti-angiogenesis effect of metronomic chemotherapy
day 1 Day 14day 7 Day 21
Vascular endothelial cell
Conventional Chemotherapy
Metronomic Chemotherapy
![Page 9: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/9.jpg)
Adjuvant therapy”
• No distant metastasis by imaging
• Destroying „micrometastases „– with combined therapy
• Minimising late onset side effects e.g. cardiotoxicity
Neoadjuvant tharapy Decreasing tumor mass
Risk of acute toxicity against operability e.g. organ preservating surgery
Short term therapy
Palliativtharapy, metastatic cases
• Longest survival with best possible QoL
• Managing side effects is essentialq
• Monothharapy, sequential tharapy
![Page 10: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/10.jpg)
INCREASED EFFICACY
Different mechanisms of action Compatible side effects
Different mechanisms of resistance
ACTIVITY SAFETY
Principles of chemotherapy
Aim of combination therapy
![Page 11: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/11.jpg)
Mucositis
Nausea/vomiting
Diarrhea
Cystitis
Sterility
Myalgia
Neuropathy
Alopecia
Pulmonary fibrosis
Cardiotoxicity
Local reaction
Renal failure
Myelosuppression
Phlebitis
Principles of chemotherapy
Side effects of chemotherapy
![Page 12: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/12.jpg)
Human cancers are heterogeneous
Meric-Bernstam, F. & Mills, G. B. (2012) Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.127
![Page 13: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/13.jpg)
action
In case of success: became an innovativ medicine, and become
part of the standard of care
Old paradigm: „Trial and Error Medicine"
Personalized medicine
![Page 14: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/14.jpg)
Personalized medicine
New paradigm: Personalized Medicine
Testing required, which leads to adequatetreatment
observation testtreatment Predictive for
the response
The „Trial and Error Medicine” circle disrupted
![Page 15: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/15.jpg)
Diagnosis Saves lifeyears
Diagnosis Saves money
Personalized medicine
Why is it important?
![Page 16: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/16.jpg)
Selection of the appropriate drug
Breast cancer trastuzumab HER2
Drug dose
Colon cancer irinothecan UGT1A1
Drug efficacy
CML Gleevec® Quant BCR-ABL
Stage
CLL Campath® Minimal residual Illiness
Relapse risk
Breast cancer Oncotype DX® Multivariance Analysis
Risk factor
Breast cancer BRCA testing Risk analysis
Personalized medicine test examples
![Page 17: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/17.jpg)
Definition of presonalized medicine:
“Personalized medicine refers to
the tailoring of medical
treatments to the individual
characteristics of each patient …
Preventive or therapeutic
interventions can then be
concentrated on those who will
benefit, sparing expense and side
effects for those who will not.”
President’s Council of Advisors on Science and
Technology (PCAST), Priorities for Personalized
Medicine, September, 2008
![Page 18: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/18.jpg)
LUX-Lung 2: Effect of Afatinib in a patient with brain metastasisfrom EGFR L858R mutant lung cancer
Yang CH et al. Poster number: 8026. Presented at the American Society of Clinical Oncology, Chicago, Illinois, 2008
Baseline After 1 cycle
![Page 19: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/19.jpg)
Personalized medicine…why is it important?
In routine cancer treatments result low response rates
Tumor response rates arebetween 20-75%
It depends on drugs and types of disease
![Page 20: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/20.jpg)
Oncology – the fastest growing therapeutic area
TRENDS
-aging society
- increasing number of combinedtherapies
- multiple lines of therapy
- increasing number of expensive drugs
- More frequent use of drugs
- China – 100 millions of wealthy peopleor people with health insurance
![Page 21: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/21.jpg)
Two main groups of currently administered cancertreatments (mAb vs TKI)
Monoclonal antibodies
Specific inhibition
High molecular weight proteins
Parenteral administration
ADCC effect, Activating immune system
No drug interactions
Question of biosimilarity
Low molecular weight TKI
Multiple receptor inhibition
Small promiscuous molecules
Per os administration
No proven ADCC effect, and immunesystem activation
Multiple drug interactions
Question of generics
![Page 22: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/22.jpg)
Targeted therapies resulted in significant survival benefit
Cancer types Median survival(moths)
Before Now Reference
Breast cancer, all 12 >56 Giordano, 2004
Colorectal cancer 12 >30 Grothey, 2009
Lung cancer (NSCLC ) 10,1 11,3 Pirker, 2009
Ovarian cancer 12 36 Hoskins, 2009
Renal cancer 14 28 Cella, 2008
Head and neck 29 49 Bonner, 2006
C. Zielinski et al,Presented at DGHO 2009
![Page 23: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/23.jpg)
Identificating tumormarkers lead us to personalizedmedicine: well defined patients, market segmentation
-Successful examples: HER2 and KRAS mutation analysis
- Limited number of proper patients for targeted therapy– increasing segmentation ofpharmaceutical market
- Administration of more efficient drugs in well characterised groups of patients
-Possibility to conduct clinical trials with limited number of patients, with the same statistical power (right drug for the right patient), but therefore more complicated and expensive studies are expected (more samples, biomarker analysis)
-The increased segmentation of cancer drug market results in decreased profitability of the newly developed drugs, moreover there is a strong pressure on prices after commercial availability drug.
- Faster government approval of the newly developed drug is required for the wellcharacterised patient groups
- Complexity of diagnostis tests (cost, logistics, validation, wide availability).
![Page 24: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/24.jpg)
Douglas Hanahan, Robert A. Weinberg ; Hallmarks of Cancer: The Next Generation cell.2011.02.013
Therapeutic Targeting of the Hallmarks of CancerDrugs that interfere with each of the
acquired capabilities necessary for tumor growth and progression.
![Page 25: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/25.jpg)
Targeted therapy
• The first molecular target for cancer therapy was the nuclear receptor for the female sex hormone estrogen (ER), required by many breast cancers for growth.
• Estrogen bound to its nuclear receptor (ER) will activate expression of specific genesinvolved in cell growth and proliferation.
![Page 26: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/26.jpg)
Célzott terápia az ösztrogén receptoron• Selective Estrogen Receptor Modulators (SERMs)
– tamoxifen
• Estrogen Receptor inhibitors– fulvestrant
Inhibitors of estrogen synthesis – aromatase inhibitors– anastrozole
– letrozole
– Exemestane
brain
liver
Fat tissue
hair
Breast cancer
muscles
breast
![Page 27: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/27.jpg)
TK TKATP ATP
Cell Proliferation
Antiapoptosis
Angiogenesis
Gene Transcription
Cell Cycle Progression
+
MetastasesSurvival
Tumor Cell Stimulation
![Page 28: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/28.jpg)
TK TK TK
Inhibition of TK receptor singaling
-- -
tyrosine kinase
inhibitors
“-ibs”
Anti- mAbs
“-mab”
Anti-ligand mAbs
“-mab”
AT
P
![Page 29: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/29.jpg)
Side effect of targeted therapy: mucositis
29
![Page 30: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/30.jpg)
Hand-foot syndrome targetettherapy AE.
30
![Page 31: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/31.jpg)
A good example for personalizedmedicine: Herceptin
![Page 32: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/32.jpg)
Changing paradigm: Breast cancer is not a homogenous disease
HER2-positive breast cancer is a new entity
![Page 33: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/33.jpg)
Role of HER2
-Overexpression of HER2 is an early event during the curse of the disease
- HER2 overexpression is a worse prognostic marker
-To prove HER2 overexpression or gene amplification is prerequisite for antiHER2 treatment
- One quarter of breast cancers are HER2positive
- Knowing HER2 status is required for therapeutic decision
![Page 34: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/34.jpg)
Herceptin: one target - four mechanism
Avoiding p95HER2 (truncated receptor)Inhibition of proliferation
Activating ADCC mediatec killer cellsInhibiton of angiogenesis
![Page 35: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/35.jpg)
Therapeutic decision based on biomarkersleads to significantly improved
therapeutic results.
![Page 36: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/36.jpg)
The standard therapy of HER2 positve breast cancerin adjuvant setting is Trastuzumab (Herceptin)
5 large clinical trials finished with good clinical benefit
N > 13 000 patient
Herceptin therapy is recommended by all guidelines in early breast canceroverexpressing HER2
Risk of relapse decreased by 50%
Risk of death decreased to 1/4-1/3
Without HerceptinHerceptin for one year
![Page 37: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/37.jpg)
Survival benefit with Herceptin in first line treatment
Hó
nap
ok
H + P P H + D
H0648g(IHC3+ patients)
M77001
D
25
31.2
18
22.7
0
10
20
30
Marty et al 2005; Smith et al 2001
+7 months
+ 8,5 months
H: Herceptin, P: paclitaxel, D: docetaxel
![Page 38: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/38.jpg)
Median survival
BSC
0 2 4 6 8 10 12 14 16 18
Milestones in advanced gastric cancertreatment
(months)
Combined chemotherapy
+ 5-6 months
Combined chemotherapy + herceptin
+ 5-6 months
16 m
![Page 39: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/39.jpg)
Novel anti HER2 monoclonal antibodies
![Page 40: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/40.jpg)
40
Homodimers Heterodimers
Life is not for singles!
Tzahar et al. Mol Cell Biol 1996;16:5276–5287
Activation of HER2 signaling – tumorprogression
HER1:HER1
HER2:HER2
HER3:HER3HER4:HER4 HER1:HER2 HER1:HER3 HER1:HER4
HER2:HER3HER2:HER4
HER3:HER4
![Page 41: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/41.jpg)
41
Herceptin and pertuzumab binding to HER2 receptor
HER2HERCEPTIN PERTUZUMAB
Subdomain IV Dimerisation domain
HER 1,2,3 4
Herceptin inhibits activation, but notdimerisation of HER2 receptors
Pertuzumab inhibits HER2 receptor dimerisation and activation
Both drugs can activate the patient’s anti cancer immune response
![Page 42: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/42.jpg)
42
What is T-DM1?
Monoconal antibody:
HERCEPTIN
Drug target: HER2
Effective chemotherapy
(maytansine derivate)
Cytotoxic drug: DM1
Extracellularly stable, intracellularlybreaks and the chemotherapy agentwill detach
LinkerT-DM1
![Page 43: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/43.jpg)
43
TDM1 mechanism of action
1. TDM1 binds to HER2-receptor with the „trastuzumabpart”
2. TDM1-HER2 receptor is internalized via endocytosis
3. The antibody and the receptor parts are destroyed bylisosomal proteolysis
4. The citotoxic component is released from the lysosomeand acts intracellularly
![Page 44: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/44.jpg)
Another example of personalizedmedicine: history of mCRC therapy– from
chemotherapy to targeted biologicaltherapy
![Page 45: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/45.jpg)
Currently approved drugs in the treatment of mCRC
5-FU/LV Capecitabine Irinotecan
OxaliplatinBevacizumab
Ramucirumab
Cetuximab
panitumumab
AfliberceptRegorafenib
![Page 46: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/46.jpg)
Bevacizumab4
Median OS
Idő
(hó
nap
)
BSC
5-FU
30
Irinotecan1
Capecitabine2
Oxaliplatin3
Cetuximab5,6
1980s 1990s 2000s 2010
Panitumumab7
Aflibercept8
Regorafenib9
20
10
0
In the last 3 decades, therapy improvements in mCRC, resulted increased survival rates…
1. Cunningham, et al. Lancet 1998; 2. Van Cutsem, et al. BJC 2004
3. Rothenberg, et al. JCO 2003; 4. Hurwitz, et al. NEJM 2004
5. Cunningham, et al. NEJM 2004; 6. Van Cutsem, et al. NEJM 2009
7. Van Cutsem, et al. JCO 2007; 8. Van Cutsem, et al. JCO 2012
9. Grothey, et al. Lancet 2012
ramucirumab
2015
![Page 47: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/47.jpg)
Colon Cancer Genetic Pathways
CK7+/p53−/MLH-1−/BRAF-mutated/K-ras-wt/M SI
CK7+/CK20+/p53−/MLH-1+/BRAF wt/K-ras-mutated/MSS
![Page 48: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/48.jpg)
Quality of life
Patient preference
Toxicity
Tumour
burdenResecability
Tumor
localization
Tumor charateristics
Patient’s characteristics
Age
ComorbiditiesPrevious
adjuvant th.
Molecular characteristics
RAS BRAF
MSI highPerformance
status
MSI, microsatellite instability; mCRC, metastatic colorectal cancer. ; * FOLFOXIRI: oxaliplatin és irinotecan alkalamzási előírás alapján nem rendelkezik indikációval; a Roche nem javasolja ennek a protokollnak a használatát
van Cutsem et al., Ann Oncol 25 (Supplement 3): iii1–iii9, 2014; www .esmo.org/Guidelines/Pocket-Guidelines-Mobile-App accessed 11.11.2015; D Arnold Colorectal cancer case discussion ESMO 2015 ecco.hybridwebcast.com/ecc2015/library ;
How to decide about the first-line therapy in mCRC?
TRIPLET• FOLFOXIRI*
DOUBLET• FOLFOX• FOFIRI• XELOX
+/- Biological th
MONOTHERAPY• Fluoropyrimidine
![Page 49: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/49.jpg)
Reevaluation of diagnostics
The cost of medical diagnostics is less than 2% of the healthcare expenses inthe world, YET it influences more than60% of the critical treatment decisions.
![Page 50: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/50.jpg)
American goverment bailout: 8,5 trillion $(Bloomberg News)
Cost?
At the cost of the Iraq war,all cancer patients inthe world could be treated fo 20 years!
Cost of Iraq war(yet): 710 billion $(cost of war website)
Annual cost of cancer drugs: 40 billion $ (IMS)
![Page 51: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/51.jpg)
Role of immune system in tumorigenesis
Equilibrium EscapeElimination
• Effective antigeneproduction/presenting
• Sufficient effector cellactivation and function
Tumour cells
Normal cells
• The tumor escapes fromcontrol, cell lines areproliferating wich ar able todownregulate the immunesystem
Treg
• At first, immune system protects against tumors, but later it can help thetumor progresson
Vesely MD, et al. Ann Rev Immunol 2011;29:235–271
• Instability• Tumor heterogenity• Immun selection
Daganat felismerés „sleeping” tumor Daganat progresszió
CD8+
T cellCD4+
T cell NK cell
![Page 52: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/52.jpg)
MHC
PD-L1
PD-1 PD-1
PD-1 PD-1
Nivolumab, PD-1 receptor inhibiting antibody
T cellreceptor
T cellreceptor
PD-L1PD-L2
PD-L2
MHC
CD28 B7
T-sejt
NFOther
PI3KDendritikus
sejtTumor sejt
IFN
IFNγR
Shp-2
Shp-2
Role of PD-1 pathway in inhibiton of antitumoralimmune system
Ribas A. N Engl J Med 2012;366(26):2517–2519
![Page 53: PRINCIPLES OF ONCOLOGICAL TREATMENT DANK ...treatments to the individual characteristics of each patient … Preventive or therapeutic interventions can then be concentrated on those](https://reader034.fdocuments.in/reader034/viewer/2022042401/5f10a4997e708231d44a1d34/html5/thumbnails/53.jpg)
Thank You